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Abstract
Purpose: The aim of this study is evaluate the efficacy of TachoSil® patches in controlling suture-
hole bleeding after elective infrarenal abdominal aortic aneurysm (AAA) replacement with Dacron
graft.
Materials and methods: Patients undergoing elective replacement of infrarenal AAA with
Dacron grafts were prospectively randomized to TachoSil® patches (Group I) or standard
compression with surgical swabs (Group II).
We evaluated time to haemostasis, blood loss during the operation, blood loss after cross-clamp
removal, duration of operation, drain volume, requirement for blood transfusion and surgeons
rating of efficacy.
Results: Twenty patients were randomized (10 patients in each treatment Group). The mean time
to haemostasis was 264 ± 127.1 s (range: 180-600 s) in Group I and 408 ± 159.5 s (range: 120-720
s) in Group II (p = 0.026); mean blood loss during the operation was 503.5 ± 20.7 cc (range: 474-
545 cc) in Group I and 615.7 ± 60.3 cc (range: 530-720 cc) in Group II (p < 0.001); mean blood loss
after cross-clamp removal was 26.5 ± 4 g (range: 22-34 g) in Group I and 45.4 ± 4.6 (range: 38-52
g) in Group II (p < 0.001) and mean drain volume was 116.7 ± 41.4 cc (range: 79-230 cc) in Group
I and 134.5 ± 42.8 cc (range: 101-250 cc) in Group II (p = 0.034). There were no serious adverse
events associated with use of TachoSil® patches.
Conclusion: For patients undergoing aortic reconstruction with Dacron grafts, TachoSil® patches
were found to be safe and effective for the control of suture-hole bleeding.
Introduction
Suture-hole bleeding, during aortic surgery, represents a
risk for the patient in terms of blood loss and prolonga-
tion of operation due to additional suturing with danger
of iatrogenic stenosis. Although this complication is more
relevant in the use of expanded polytetrafluoroethylene, it
may occur also after Dacron graft replacement [1,2]. Typ-
ically suture-hole bleeding is managed by compression
with surgical swabs and reversal of heparin. Other meth-
ods such as application of oxidised cellulose, gelatine
sponge, different forms of collagen and glues have also
been tried with variable success [3].
TachoSil® (haemostatic surgical patch; Nycomed, Linz,
Austria) is a fixed combination of a collagen matrix coated
with the coagulation factors, human fibrinogen and
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portive treatment in surgery for improvement of haemos-
tasis, to promote tissue sealing, and for suture support in
vascular surgery where standard techniques are insuffi-
cient [4]. It is a ready-to-use and absorbable haemostatic
dressing. The aim of the study was to compare the efficacy
and safety of TachoSil® patches against standard surgical
compression to control the suture-hole bleeding from
Dacron grafts in aortic surgery.
Materials and methods
Between June 2007 and June 2008 a total of 20 patients
with intact infrarenal abdominal aortic aneurysm (AAA)
were randomized in the same center. Mean age was 72.8
± 6.1 years (range: 63-80 years) in the TachoSil® Group
(Group I) and 72.6 ± 4.5 years (range: 67-82 years) in the
standard compression with surgical swabs Group (Group
II). Mean transverse diameter was 7.1 ± 1.2 cm (range:
5.6-9 cm) in Group I and 6.8 ± 1 cm (range 5.5-8.6 cm) in
Group II. Seventeen were male and 3 female (Table 1), 18
patients received an aorto-aortic Dacron straight tube (Fig
1) and two an aorto-bifurcated Dacron graft. All prosthe-
sis used were Gelsoft™ Plus gelatin impregnated knitted
graft (Vascutek, Terumo Company, Glasgow, Scotland).
No patients were excluded after the randomization. Aortic
and femoral anastomosis were evaluated. The anastomo-
sis were performed using 2-0 or 5-0 prolene sutures. Sys-
temic heparin (50-100 UI/Kg) was infused in aorto-
bifurcated Dacron graft; in these two cases it hasn't be
reversed. The local ethics committee approved the study,
and informed written consent was obtained before inclu-
sion from all patients. Allergy to any component of
TachoSil® was considered for exclusion prior the randomi-
zation. Patients, who did not require additional haemo-
static measures on releasing the clamps, were also
excluded from the study. Likewise patients with alteration
of clotting parameters or liver diseases were excluded from
the study. Sealed code envelope method was used to ran-
domize patients to either treatment with TachoSil® use or
to standard compression with surgical swabs. The rand-
omization code envelopes were opened just before the
application of haemostatic measures. The nature of the
treatments precluded blinding of the study.
TachoSil® patches were applied in Group I after moisten-
ing with physiological saline after clamp removing. Dos-
age (the number of patches used) depended on the size of
the area to be covered. One patch of TachoSil® is 9.5 × 4.8
× 0.5 cm in size. It contains a fixed combination of a col-
lagen matrix coated with the coagulation factors, human
fibrinogen (5.5 mg/cm2) and human thrombin (2.0 IU/
cm2). TachoSil is produced by Nycomed (Linz, Austria),
and is a further development of the TachoComb® and
TachoComb H® products and is free of bovine compo-
nents.
The moistened patch of TachoSil® was applied with the
yellow active side onto the wound surface after blood and
other fluids were cleaned from the wound area. The patch
had to extend around the anastomosis and left in loco for
3 min. After this period haemostasis was assessed. If hae-
mostasis was not achieved by the time of this first look
another 2 min of compression was applied. If haemostasis
was still insufficient, the first patch was replaced with a
new and left in loco for a maximum of 5 min before con-
sidering other methods. If a patch became displaced by
bleeding during the first 5 min, it was replaced with a new
piece. Patients in the control arm received compression
with 10 × 10 cm surgical swabs. If haemostasis was subop-
timal at the end of 10 min then other methods were
adopted as necessary.
The main outcome measured was time to achieve hae-
mostasis at the suture line. Haemostasis was defined as
the time when the abdominal or inguinal wound was
completely dry or sufficiently dry to complete the opera-
tion without additional haemostatic measures.
Statistical analyses on blood loss during the operation,
blood loss after cross-clamp removal, duration of opera-
tion, drain volume, requirement for blood transfusion
and surgeons rating of efficacy were performed. Blood loss
during operation was measured by using cell saver device
(Dideco Electa, Sorin® Group, Italy) and blood loss after
cross-clump removal was measured by weighing the
swabs used in the relevant wound from the time TachoSil®
or compresses were applied until achieving haemostasis.
Duration of the operation was measured from the time of
incision to the completion of skin suture. The drainage
Aorto-aortic Dacron straight tube and TachoSil® applicationFigure 1
Aorto-aortic Dacron straight tube and TachoSil® 
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uated at the time of removal after 36 hours. Surgeons rat-
ing of hemostasis efficacy was grade from 3 to 0: 3-"very
good"; 2 - "good"; 1 - "satisfactory" and 0 - "unsatisfac-
tory". All the variables (time to haemostasis, blood loss
during the operation, duration of operation, drain vol-
ume, requirement for blood transfusion and surgeons rat-
ing of efficacy) of the two treatment groups were analyzed
using SAS ®software (Version 9.2, SAS institute Inc., Cary
NC, USA). Wilcoxon rank sum test was used to evaluate
the association between each variable in the two treat-
ment Group. Graft sizes were recorded. In 18 cases a
straight Dacron graft tube was used, in 2 cases a bifurcated
graft. One bifurcated graft was used in the Group I and the
other one in Group II. All patients underwent same anti-
biotic protocol.
Results
Ten patients were randomized in each treatment group of
the study. In Group I, one patch was used in 5 patients,
two patches in 4 patients and three patches in 1 patient.
Postoperative clotting parameters were not altered by
application of the patches. There were no instances of
intravascular thrombosis or embolism subsequent to the
application of TachoSil. The mean time to haemostasis
was 264 ± 127.1 s (range: 180-600 s) in Group I and 408
± 159.5 s (range: 120-720 s) in Group II. The Wilcoxon
test based on the 20 patients with assessment of time to
haemostasis showed statistical significance (p = 0.026).
Complete haemostasis was achieved within 3 min in 4/10
patients (40%) in Group I and 1/10 patients (10%) in
Group II. In Group I other 5/10 patients (50%) achieved
haemostasis at the second look after 5 min making a total
of 90% haemostasis after 5 min. In Group II 2/10 more
patients (20%) achieved complete haemostasis at the sec-
ond look adding to a total of 30% haemostasis after 5
min. Haemostasis was achieved within 5 min in 90% of
the patients in Group I compared to only 70% within 7
min in Group II. The mean blood loss during the opera-
tion was 503.5 ± 20.7 cc (range: 474-545 cc) in Group I
and 615.7 ± 60.3 cc (range: 530-720 cc) in Group II with
significant statistical difference (p < 0.001). Mean blood
loss after cross-clamp removal was 26.5 ± 4 g (range: 22-
34 g) in Group I and 45.4 ± 4.6 g (range: 38-52 g) in
Group II (p < 0.001). Mean time of operation was 111.7
± 15 min (range: 99-150 min) in Group I and 119.9 ± 20.7
min (range: 95-170 min) in Group II and showed no sta-
tistical difference (p = 0.199). Mean drainage volume at
36 hours was 116.7 ± 41.4 cc (range: 79-230 cc) in Group
I and 134.5 ± 42.8 cc (range: 101-250 cc) in Group II (p =
0.034). Perioperative blood transfusion was 1.3 units
(range: 0-2 units) in Group I and 1.4 units (range: 0-3
units) in Group II (p = 0.968) (Table 2).
Table 1: Patient demographics and comorbidity conditions.
Factor TachiSil®, n (%)* Control, n (%)* P
Age, mean years 72.8 (63-80) 72.6 (67-82) NS
Male gender 8 (80) 9 (90) NS
Smoking history 4 (4 5 NS
Hypertension 6 (60) 5 (50) NS
Diabetes Mellitus 0 (0) 1 (10) NS
COPD 2 (20) 3 (30) NS
CAD 0 (0) 0 (0) NS
Cerebrovascular disease 0 (0) 0 (0) NS
Renal Failure 0 (0) 0 (0) NS
Aneurysm size, median cm 7.1 (5.6-9) 6.8 (5.5-8.6) NS
COPD: chronic obstructive pulmonary disease; CAD: coronary artery disease
* Categoric data presented as number (%), continous data presented with the range
Table 2: Variables measured.
Variable TachoSil® (n = 10) Control (n = 10) P
Time to haemostasis (s) 264.0 ± SD 127.1 408 ± SD 159.5 0.026
Blood loss during the operation (cc) 503 ± SD 20.7 615 ± SD 60.3 <0.001
Blood loss after cross-clump removal (g) 26.5 ± SD 4 45.4 ± SD 4.6 <0.001
Duration of operation (min) 117 ± SD 15 119.9 ± SD 20.7 0.199
Drain volume (cc) 116.7 ± SD 41.4 134.5 ± SD 42.8 0.034
Requirement for blood transfusion 1.3 ± SD 0.8 1.4 ± SD 0.8 0.968
Surgeons rating of efficacy 2.6 ± SD 0.5 2.2 ± SD 0.8 0.257
SD: standard deviation; n: numbers of patients; sec: seconds; cc: cubic centimetres; g:grams; min: minutes.Page 3 of 5
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was registered in the two arms. In the sixth post-operative
day, we registered, in Group II, a case of myocardial inf-
arction treated with medical therapy. One case of renal
failure requiring dialysis was seen in Group II. The non-
serious adverse events were equally distributed between
the two treatment groups. No adverse events were consid-
ered related to the test treatment.
Discussion
TachoSil® patches may be effective in delivering drugs
locally. In this study TachoSil® was used to provide fibrin-
ogen and thrombin locally at the site of bleeding. Upon
contact with fluid the clotting factors of TachoSil® dissolve
and form a fibrin network, which glues the collagen
sponge to the wound surface. Combining the clotting fac-
tors in a collagen patch provides a high concentration of
clotting factors at the site where it is specifically needed.
The haemostatic effectiveness of using TachoSil® has pre-
viously been proved in clinical studies [5-7]. Liquid fibrin
glue preparations are likewise found to be effective in
achieving haemostasis [8-10]. Other attempts used to
control suture hole bleeding are ethylcyanoacyrlate glue,
different forms of collagen, oxidized cellulose, topical
thrombin and gelatine sponge or fibrin [11]. However,
combining fibrin glue components in a collagen patch
facilitates ease of application. Recently TachoSil® patches
was found significantly superior compared to conven-
tional haemostatic fleece material for control of bleeding
in cardiovascular surgery [12]. Despite the small number
of patients enrolled, the present study showed that
TachoSil® significantly reduces the time to haemostasis. In
addition both intra and postoperative bleeding were sub-
stantially reduced in the Group I. TachoSil® was well toler-
ated and none of the adverse events observed in Group I
were considered related to test treatment.
Conclusion
In our experience, TachoSil® was found to be safe and
effective for the control of suture-hole bleeding in patients
undergoing vascular reconstruction with Dacron grafts.
Further studies with larger sample size are required to con-
firm the efficacy of TachoSil® patches in controlling
Dacron suture-hole bleeding after AAA open repair. More-
over, TachoSil® could be proven as an useful tool in spe-
cific conditions such as coagulopathy and redo aortic
surgery.
List of Abbreviations used
cm: centimeters; UI: International Units; mg: milligrams;
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Kg: kilograms.
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